Citius Oncology Inc (CTOR)

Currency in USD
0.63
+0.03(+5.59%)
Closed·
0.64+0.01(+2.33%)
·
Earnings results expected in 15 days
CTOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.550.68
52 wk Range
0.492.25
Key Statistics
Prev. Close
0.59
Open
0.64
Day's Range
0.55-0.68
52 wk Range
0.49-2.25
Volume
94.79K
Average Volume (3m)
67.47K
1-Year Change
-69.4175%
Book Value / Share
0.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTOR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.00
Upside
+534.92%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Citius Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.00
(+534.92% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy6.00+852.38%-UpgradeSep 23, 2025

Earnings

Latest Release
May 15, 2026
EPS / Forecast
-0.27 / --
Revenue / Forecast
1.67M / 16.76B
EPS Revisions
Last 90 days

CTOR Income Statement

Compare CTOR to Peers and Sector

Metrics to compare
CTOR
Peers
Sector
Relationship
P/E Ratio
−1.3x−7.3x−0.4x
PEG Ratio
0.04−0.010.00
Price/Book
1.6x2.6x2.6x
Price / LTM Sales
9.9x6.6x3.0x
Upside (Analyst Target)
-90.3%56.0%
Fair Value Upside
Unlock−5.8%9.1%Unlock

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
890.44K0.96%527.41K
Other Institutional Investors
88.77M95.47%52.58M
Public Companies & Retail Investors
3.32M3.57%1.97M
Total
92.98M100.00%55.07M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Citius Pharmaceuticals, Inc.71.04%66,049,61539,121
Armistice Capital Master Fund Ltd.10.00%9,299,9175,508

People Also Watch

12.75
MNRO
+4.08%
6.220
ILU
+2.81%
5.00
LENZ
-5.75%
11.90
REPL
+6.25%
20.74
ANIK
+7.55%

FAQ

What Is the Citius Oncology (CTOR) Stock Price Today?

The Citius Oncology stock price today is 0.63 USD.

What Stock Exchange Does Citius Oncology Trade On?

Citius Oncology is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Citius Oncology?

The stock symbol for Citius Oncology is "CTOR."

What Is the Citius Oncology Market Cap?

As of today, Citius Oncology market cap is 55.07M USD.

What Is Citius Oncology's Earnings Per Share (TTM)?

The Citius Oncology EPS (TTM) is -0.50.

When Is the Next Citius Oncology Earnings Date?

Citius Oncology will release its next earnings report on Aug 18, 2026.

From a Technical Analysis Perspective, Is CTOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Citius Oncology Stock Split?

Citius Oncology has split 0 times.

What is the current trading status of Citius Oncology (CTOR)?

As of Aug 03, 2026, Citius Oncology (CTOR) is trading at a price of 0.63 USD, with a previous close of 0.59 USD. The stock has fluctuated within a day range of 0.55 USD to 0.68 USD, while its 52-week range spans from 0.49 USD to 2.25 USD.

What Is Citius Oncology (CTOR) Price Target According to Analysts?

The average 12-month price target for Citius Oncology is 4.00 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +534.92% Upside potential.

What Is the CTOR Premarket Price?

CTOR's last pre-market stock price is 0.64 USD. The pre-market share volume is 1,760.00, and the stock has decreased by 0.05, or 8.47%.

What Is the CTOR After Hours Price?

CTOR's last after hours stock price is 0.64 USD, the stock has decreased by 0.01, or 2.33%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.